Clinical Trials Logo

Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to Non-Hodgkin's Lymphoma.

Filter by:

NCT ID: NCT01164475 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Start date: October 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study was to compare the responses of 2 different doses of plerixafor in patients with Non-Hodgkin's Lymphoma (NHL) who received an autologous stem cell transplant.

NCT ID: NCT01164345 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Mozobil for Autologous Stem Cell Mobilization

Start date: June 2010
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate Plerixafor (MOZOBIL) plus recombinant human G-CSF (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL) patients for autologous transplantation.

NCT ID: NCT01153971 Completed - Clinical trials for Non-Hodgkin's Lymphoma

A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.

NCT ID: NCT01149668 Completed - Multiple Myeloma Clinical Trials

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.

NCT ID: NCT01144754 Terminated - Lymphoma Clinical Trials

Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT

Start date: February 2009
Phase: N/A
Study type: Observational

This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months. Patients in this study are enrolling for the collection of their data on observations made during normal clinical practice.

NCT ID: NCT01144364 Completed - Clinical trials for Non-Hodgkin's Lymphoma

A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Start date: January 2004
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

NCT ID: NCT01133158 Completed - Clinical trials for Non-Hodgkin's Lymphoma

R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

Start date: July 2009
Phase: Phase 2
Study type: Interventional

Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.

NCT ID: NCT01118845 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

NCT ID: NCT01109069 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Start date: June 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

NCT ID: NCT01103388 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Rituximab Maintenance After Autologous Transplantation

Start date: August 2003
Phase: Phase 3
Study type: Interventional

The goal of this clinical research is to see if Rituxan (rituximab) therapy given after high dose chemotherapy and transplant of a patients own stem cells will prevent or delay the return of the lymphoma.